Welcome to our dedicated page for P3 HEALTH PARTNERS news (Ticker: PIIIW), a resource for investors and traders seeking the latest updates and insights on P3 HEALTH PARTNERS stock.
P3 Health Partners Inc., whose warrants trade on Nasdaq under the symbol PIIIW, regularly issues news and updates related to its role as a patient-centered and physician-led population health management company. Company press releases describe how P3 manages defined patient populations, particularly Medicare Advantage members under capitation arrangements, and how this focus is reflected in its financial and operating metrics.
News items have included preliminary financial results, outlook commentary and discussions of at-risk Medicare Advantage membership growth. In these communications, P3 has highlighted revenue trends, net income or loss, Adjusted EBITDA, and Adjusted EBITDA per member per month (PMPM), along with explanations of how these non-GAAP measures relate to its value-based care model. The company has also discussed the impact of COVID-19 on its patient base and cost structure, especially for older adults with chronic illnesses.
Investors following PIIIW-related news can also see announcements about corporate events such as participation in healthcare investor conferences and updates on business combinations and accounting periods. These releases provide context on how P3 presents its strategy, capital efficiency and national expansion efforts within its population health management framework.
This news page aggregates such disclosures so readers can review company-issued information on operating performance, at-risk membership metrics, financing developments and governance changes. By reviewing these updates in one place, users can better understand how P3 Health Partners communicates its progress and challenges in managing value-based care populations while its warrants trade under the PIIIW symbol.
P3 Health Partners reported a strong revenue growth of 46% for Q4 2021 and 32% for the full year, projecting 2022 revenue up to $1 billion (a 56% increase). The company aims for 95,000 at-risk Medicare Advantage members by year-end, a 42% rise. Adjusted EBITDA is expected to improve significantly, with profitability anticipated by 2024. Despite a net loss of up to $95 million for Q4, a robust cash position of $140 million at year-end supports operations. P3 will file for a late 10-K extension, expecting to release detailed results by April 15, 2022.
P3 Health Partners, Inc. (NASDAQ: PIII), a physician-led population health management company, announced its participation in three investor conferences in March 2022. The company will present at the Cowen 42nd Annual Healthcare Conference on March 9, attend the 34th Annual ROTH Conference on March 14 in Dana Point, CA, and participate in the Barclays Global Healthcare Conference on March 16 in Miami, FL. Live webcasts will be available on P3’s investor relations website, providing access to presentations and replays.